[ad_1]
Patient’s condition improved after doctors at Abu Dhabi Stem Cell Center performed transplant earlier this month
Physicians at the Abu Dhabi Stem Cell Center (ADSCC), part of PureHealth Group, have successfully performed the region’s first bone marrow transplant for a patient suffering from multiple sclerosis (MS), highlighting Abu Dhabi as a center of excellence The growing status of health care center and science center of life.
A bone marrow transplant performed under the Abu Dhabi Bone Marrow Transplantation (AD-BMT) program was a major achievement, demonstrating significant advances in cell therapy and regenerative medicine in the treatment of a range of diseases, including cancer and disorders of the immune system.
Doctors performed an autologous hematopoietic stem cell transplant (AHSCT) earlier this month, and the patient reported improvement. Developed by ADSCC, the therapy aims to “reset” a person’s immune system and could be used in patients with relapsing forms of multiple sclerosis.
The Abu Dhabi Bone Marrow Transplant Program at ADSCC was established in 2020 to provide autologous and allogeneic HSCT in adults and children as a comprehensive program and to implement different forms of cell therapy such as adoptive cell transfer. MS patients were treated by the center’s program team, led by AD-BMT program director Dr. Fatima Al Kaabi, in collaboration with the neurology team.
Dr. Al Kaabi said, “At ADSCC, we are committed to ensuring that the AD-BMT program meets the highest standards of quality and patient satisfaction throughout all steps of the process, including treatment, aftercare and follow-up. With this new therapy, we expand Our world-class capabilities represent hope and aim to improve the quality of life for everyone.”
Dr Yendry Ventura, Chief Executive Officer of ADSCC said: “We are very proud of our achievement in being the first center in the region to perform BMT on MS patients. We are very proud to be able to carry out such a life-saving treatment in Abu Dhabi Proud. We are grateful for the vision of the UAE’s wise leadership and the support of PureHealth management for making this possible.”
Shaista Asif, Group Chief Operating Officer, PureHealth Group, noted: “The timing of a revolutionary bone marrow transplant for MS patients in the UAE could not be more opportune as we mark five decades of progress in the UAE’s field. Wise and wealthy in the UAE Led by Foresight, PureHealth and its subsidiaries are committed to raising the benchmark for healthcare excellence to increase efficiency across the healthcare value chain. In line with our commitment to longevity science, this is a step forward in improving the average healthy lifespan in the country An important step forward.”
According to the updated 2019 guidelines of the European Organization for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT), the procedure performed by the ADSCC is a “standard of care” rather than merely a “clinical option”, a review Clinical evidence of AHSCT in MS patients. It is an established and effective treatment for highly active relapsing-remitting multiple sclerosis (RRMS) in which at least one disease-modifying treatment has failed. EBMT promotes scientific excellence to further improve stem cell transplant outcomes, while ASBMT works to advance scientific and clinical care for patients in need of blood and bone marrow transplants.
ADSCC continues to deliver advanced treatments such as extracorporeal photofractionation therapy in the UAE and is the only center under the PureHealth Group with two open clinical trials. To date, ADSCC under the AD-BMT program has treated 13 cancer patients and one MS patient.
[ad_2]
Source link